VEGF-A modified mRNA in Cardiovascular Disease

Time: To be announced
Where:
To be announced
Speaker:

Abstract

AstraZeneca has over the last years developed a therapeutic drug of Vascular Endothelial Growth Factor (VEGF-A) mRNA, known as AZD8601. This has been performed in partnership with Moderna Therapeutics, Inc. VEGF-A is a well-studied protein known to stimulate angiogenesis. Intracardiac delivery of modified mRNA encoding for VEGF-A achieve a local transient expression of VEGF-A, and this is thought to improve ventricular function in patients following a myocardial infarction. The final aim is to regenerate damaged heart tissue and treat patients. Extensive pre-clinical and clinical data from the Ph1 study will be presented. The study for the EPPICURE Ph2a study in CABG patients is on-going and the future plans for the mRNA VEGF-A project is to be discussed.

Hosted By

ELRIG
The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Login
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021